Key points
- Mounjaro contains tirzepatide; Ozempic contains semaglutide.
- Both have adult type 2 diabetes indications.
- Ozempic’s current monograph also defines cardiovascular and kidney risk-reduction roles.
The direct answer
Mounjaro and Ozempic overlap in adult type 2 diabetes care, but ingredient, mechanism, evidence, instructions and monograph-defined roles differ. Neither is a universal winner.[1][2]
| Question | Mounjaro | Ozempic |
|---|---|---|
| Ingredient | Tirzepatide | Semaglutide |
| Receptor activity | GIP and GLP-1 | GLP-1 |
| Route / frequency | Injection / weekly | Injection / weekly |
| Indication context | Glycemic control in adults with type 2 diabetes | Type 2 diabetes plus defined cardiovascular and kidney roles |
How to compare evidence responsibly
First ask whether evidence is direct or cross-trial. Then check population, background treatment, outcome, duration and adverse-event context. Finally connect those results to the current Canadian monographs and the individual clinical question.[1][2]
What individual assessment adds
The prescriber reviews current diabetes treatment, goals, other medicines, hypoglycemia risk, relevant cardiovascular and kidney context, contraindications, monitoring, tolerability and preferences. A comparison table cannot perform that assessment.
Verify both product and payer
Ask the pharmacy for the exact cash price and the payer for the exact DIN criteria. Availability and reimbursement can differ even when two products share a treatment setting.[3][4][5]
Sources
- Mounjaro (tirzepatide injection) Product MonographHealth Canada / Eli Lilly Canada · Checked August 14, 2026
- Ozempic (semaglutide injection) Product MonographHealth Canada / Novo Nordisk Canada · Checked August 14, 2026
- Understanding health insuranceFinancial Consumer Agency of Canada · Checked August 14, 2026
- Check medication coverageGovernment of Ontario · Checked August 14, 2026
- PharmaCare Formulary SearchGovernment of British Columbia · Checked August 14, 2026